Project Grant R44AI129024

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund the validation of a novel treatment for glioblastoma (GBM) using oncolytic Zika virus. The awardee, Up Oncolytics, Inc., will conduct IND-enabling experiments to prepare this potential treatment for clinical trials. Key products or services to be delivered include demonstrating...

This $781,718 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel T cell-based vaccine to prevent Dengue virus (DENV) and Zika virus (ZIKV) infection. The award aims to design a vaccine that expresses ubiquitinated and rearranged ZIKV/DENV1-4 non-structural protein 3 (NS3) to induce cytotoxic T lymphocyte (CTL) responses without causing...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel high-throughput screening (HTS) assay platform that can directly monitor drug-induced changes in RNA levels of dengue and influenza viruses. The $300,000 award to Lucerna Inc., a minority-owned small disadvantaged business, will fund the creation of this HTS-compatible cell-based reporter system to...

This Project Grant award of $3,305,720.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective is to define the impact of maternal viral infections and inflammation on immune programming within the fetal brain and lymphoid organs in a non-human primate (NHP) model. The key products and services to be delivered under this 5-year grant include: Using an ex vivo microculture model to...

Novelmed Therapeutics, Inc. was awarded a $900,000 Project Grant from the National Institutes of Health's National Institute on Aging to develop a selective inhibitor of the alternative pathway of complement as a treatment for Neuromyelitis Optica Spectrum Disorder. Under the grant, Novelmed will conduct preclinical studies to evaluate its lead drug candidate NM5072, including in vitro and ex vivo assays to confirm the drug's mechanism of action and selective inhibition of the alternative...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $431,750 R21 project grant (CFDA 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders) to Rutgers, The State University of New Jersey to study the role of the RIPK3 protein in protecting neurons from excitotoxicity during Zika virus infection. The two-year project will use a combination of pharmacogenetics, imaging, molecular biology, and electrophysiology to investigate how RIPK3...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $683,995.00 to fund research to develop novel therapeutics targeting human cytomegalovirus (CMV) infections. The research focuses on characterizing the mechanism of action and optimizing a series of N-arylpyrimidinamine (NAPA) compounds that demonstrated potent anti-CMV activity in a high-throughput screening assay....

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a new antisense oligonucleotide (ASO) therapeutic for Dravet syndrome. The $391,903 award aims to characterize the pharmacokinetics and pharmacodynamics of this ASO that targets the upstream open reading frame of the SCN1A gene to upregulate the...

The National Institute of Child Health and Human Development (NICHD) awarded a $2,474,368 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to Research Triangle Institute (RTI International) to conduct longitudinal research on the long-term impact of Congenital Zika Syndrome (CZS) and associated health outcomes. The grant will enable RTI, in collaboration with the Altino Ventura Foundation in Brazil and researchers from the University of North Carolina and...

This $1,000,000 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports research and development efforts by Akanocure Pharmaceuticals Inc. to optimize a novel, broad-spectrum antiviral and immunomodulatory agent for oral administration against coronaviruses. The project focuses on lead optimization, including the design, synthesis, and testing of analogs with improved drug-like properties for...